Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
4
×
drugs
4
×
life sciences
national blog main
alnylam pharmaceuticals
boston
boston top stories
clinical trials
rna interference
aminolevulinic acid
biotech
fda
givosiran
paul matteis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
crispr
cystic fibrosis
cystic fibrosis foundation
evercore isi
evolocumab
gilead sciences
heart attack
hepatitis c
incivek
inclisiran
jeff leiden
joseph swartz
kayldeco
matt emmens
medicines co.
messenger rna therapeutics
national top stories
new york
new york blog main
new york top stories
What
pharmaceuticals
4
×
alnylam
drug
rna
data
interference
medicine
medicines
new
rnai
second
seek
speedy
ago
approval
based
cf
cholesterol
cleared
crisis
cystic
developer
evidence
far
fda
fibrosis
force
heart
helped
indicated
jeff
lasting
leiden
long
looms
lowering
market
medco
nasdaq
nod
Language
unknown
Current search:
pharmaceuticals
×
drugs
×
" boston blog main "
×
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug